Is TherapeuticsMD, Inc. (NASDAQ:TXMD) a buy in 2026?
Hold. TherapeuticsMD, Inc. is a wait-and-watch at today's price, not a fresh buy.
A $23M royalty stub on Mayne Pharma's women's health franchise, interesting on paper, but the cash trickle doesn't match the equity story yet.
Where TXMD is headed
TherapeuticsMD today is not the company most people remember. The commercial operation that burned through hundreds of millions trying to push IMVEXXY, BIJUVA and ANNOVERA into the menopause and contraception market got sold off to Mayne Pharma back in 2022. What's left is a shell with a royalty stream, a license agreement, and a tiny prenatal vitamin business under the BocaGreenMD and vitaMedMD labels. Eighty-four percent revenue growth on a TTM basis looks dramatic until you remember the base is microscopic and free cash flow for the trailing year was $301,250. Three hundred grand. For the whole company.
Read the full Compass Direction on TXMD
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $2.12).
See the full TXMD analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is TherapeuticsMD, Inc. (NASDAQ:TXMD) a buy in 2026?
Hold. TherapeuticsMD, Inc. is a wait-and-watch at today's price, not a fresh buy. A $23M royalty stub on Mayne Pharma's women's health franchise, interesting on paper, but the cash trickle doesn't match the equity story yet.
What is TXMD's Compass Score?
TherapeuticsMD, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for TXMD?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TXMD page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.